Introduction {#sec1-1}
============

Cervical cancer (CC) is known as the second most common gynecological malignancy of women worldwide whereas 250,000 patients approximately die from this disease annually (Jemal et al., 2011). The host response to malignant tumors involved in systemic alterations, not only changes in the microenvironment. Several studies has been established that systemic inflammation is involved in the progression of cancer at different stages such as initiation, promotion, invasion, and metastasis (Grivennikov et al., 2010). The systemic inflammation can be manifested as neutrophilia, thrombocytosis and relative lymphocytopenia detected in a complete blood count (CBC) examination (Grivennikov et al., 2010). Hematological biomarkers classified as routine laboratory tests are easily available and affordable. Serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and Glasgow Prognostic Score (GPS) are established as predictive values for numerous malignant tumors (Hefler et al., 2008; McMillan, 2013; Tas and Erturk, 2017). However, these markers were non-specific and may not always be available in secondary health services. Biopsy, as a gold standard, also needs a special facilities rarely established in remote areas. Therefore, CBC has a potential to be a hematological biomarkers in predicting the cancer progression.

Neutrophils and platelets supply the required bioactive molecules in neoplastic progression by providing angiogenic, epithelial, and stromal growth factors, as well as matrix-remodeling enzymes (Hanahan and Weinberg, 2011; Grivennikov et al., 2010). In addition, the imbalance in the innate and adaptive immune systems, as reflects by lymphocytopenia and an impaired T lymphocytic response compromises the effectiveness of host-tumor immune responses (Canna et al., 2005; Roxburgh et al., 2009). The involvement of the neutrophils, platelets and lymphocytes may represent the neoplastic progression. The progression of the malignancies to the advanced stage are marked with neutrophilia, thrombocytosis and lymphocytopenia. Therefore, the combination of lymphocytes, neutrophils, and platelets has been investigated to be an independent prognostic factor in determining the progression of malignancies (Lee et al., 2013; Smith et al., 2008).

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are calculated as neutrophil of platelet counts divided by lymphocyte counts. Neutrophils and lymphocytes are known as the primary components of the tumor-related stroma which are associated to local inflammation and immune responses, as well as reflects the balance between pro-tumor and anti-tumor status (Guthrie et al., 2013; Kwon et al., 2012). Moreover, an elevated platelet count indicates the severity of inflammation in cancer by indirectly related to pro-inflammatory mediators (mainly IL-1, IL-2, and IL-6) (Alexandrakis et al., 2003). Several studies recognized that the elevated ratio of peripheral neutrophils-to-lymphocytes (NLR) is related to poor prognostic indicator in various cancers (Guthrie et al., 2013). PLR is also reported to be associated with a poor outcome in different malignant tumors (Hong et al., 2015; Gunaldi et al., 2015). However, there is a paucity of data indicating that elevated pretreatment values of NLR and PLR are associated with unfavorable outcome or poor prognosis in cervical cancer (Zhang et al., 2014). There has not been a consistent conclusion regarding the use of NLR and PLR as predictive markers in cervical cancer (Wang et al., 2013). These discrepancies could be caused by different study designs and small sample sizes. Therefore, the purpose of this study is to investigate NLR and PLR as the hematological markers in predicting the staging of the cervical cancer.

Materials and Methods {#sec1-2}
=====================

Study Subjects {#sec2-1}
--------------

The study involved 282 patients from Sanglah General Hospital, Bali, Indonesia, over a five-year period (2013-2017). The patients were admitted with cervical cancer. The data of the cases were collected from medical records. The histopathological records of the patients were examined and classified into adenocarcinoma or squamous-cell carcinoma. The staging of cancer was stated using FIGO stage classification (stage I, II, III, and IV). The patient's completed blood counts prior to any treatment provided were recorded. Patients were excluded if they had received any cervical neoplasia treatment prior to the admission.

Patients were classified in two groups based on the staging: early (stage I-II) and advance (III-IV). Both groups were evaluated based on standard complete blood count (CBC) results using CELL-DYN Ruby System as a multi-parameter automated hematology analyzer. The demographic data collected include age, number of parity, and aged at menarche. The white blood cells (WBC), haemoglobin, red cell distributing width (RDW), absolute neutrophil count, absolute lymphocyte count, and absolute platelet count were analyzed as hematological parameters of interest. The neutrophil-to-lymphocyte ratio (NLR) was defined as the ratio between absolute neutrophil count to absolute lymphocyte count. The platelet-to-lymphocyte ratio (PLR) was determined as the ratio between absolute platelet counts to absolute lymphocyte count. Basophil-to-lymphocyte ratio (BLR) and monocyte-to-lymphocyte ratio were also investigated in this study.

Statistical Analysis and Ethical Approval {#sec2-2}
-----------------------------------------

For statistical analysis, SPSS ver. 16 was used, α=0.05. The data distribution was determined by using the Kolmogorov-Smirnov test. When found normally distributed, the variables were described with mean ± standard deviation. The not normally distributed variables were described with median (IQR). Pearson's correlation test was conducted to determine the partial correlation between the staging of cervical cancer to NLR, PLR, MLR, and BLR. The discriminative role and cut-off values of NLR, PLR, MLR, and BLR was determined using Receiver Operating Curve (ROC) analysis with Area under the Curve (AUC). The cut-off values used to define the sensitivity and specificity of each variables and risk model in multivariate analysis levels. The study was approved by the Ethics Committee of Udayana University Faculty of Medicine and the teaching hospital, Sanglah General Hospital (1335/UN14.2.2/PD/KEP/2018).

Results {#sec1-3}
=======

Subject Characteristics {#sec2-3}
-----------------------

There was no significant difference found in age between the advance stage group (53.71 ± 9.50 years-old) and the early stage group (52.40 ± 10.16). There was no significant difference in the number of parity and the histopathology between the early and the advance stage. Laboratory parameters such as WBC, lymphocytes, neutrophils, platelet, NLR, PLR, BLR, and MLR were significantly higher in the advance stage cancer group compared to the early stage group (p\<0.05). In contrast, hemoglobin was significantly lower in the advance stage group ([Table 1](#T1){ref-type="table"}).

###### 

Legend?

  Characteristics               Early (n=186)           Advance (n=96)          p
  ----------------------------- ----------------------- ----------------------- -----------------------------------------
  Age (years)                   52.40 ± 10.16           53.71 ± 9.50            0.545
  Menarche (years)              12.45 ± 0.98            12.21 ± 0.87            0.262
  Parity (n,%)                                                                  
   1                            3 (33.3%)               6 (66.7%)               0.72
   2                            63 (63.6%)              36 (36.4%)              
   3                            69 (71.9%)              9 (28.1%)               
   4                            42 (66.7%)              21 (33.3%)              
   5                            9 (60%)                 6 (40%)                 
  FIGO Stage (n,%)                                                              
   I                            78 (41.9%)              \-                      
   II                           108 (58.1%)             \-                      \-
   III                          \-                      75 (78.1%)              
   IV                           \-                      21 (21.9%)              
  Histopathology                                                                0.244
   Squamous Cell Carcinoma      111 (61.7%)             69 (38.3%)              
   Adenocarcinoma               75 (73.5%)              27 (26.5%)              
   Haemoglobin (g/dl)           11.48 ± 1.84            10.56 ± 1.83            0.030[\*](#t1f1){ref-type="table-fn"}
   White Blood Cell (10^9^/L)   8.53 ± 4.79             12.41 ± 6.04            0.001[\*](#t1f1){ref-type="table-fn"}
   Neutrophil (10^9^/L)         5.85 ± 4.71             10.14 ± 5.88            \<0.001[\*](#t1f1){ref-type="table-fn"}
   Monosit (10^9^/L)            0.57 ± 0.23             0.61 ± 0.23             0.4
   Lymphocyte (10^9^/L)         1.36 ± 0.67             1.78 ± 0.73             0.008[\*](#t1f1){ref-type="table-fn"}
   Basophill (10^9^/L)          0.05 ± 0.03             0.07 ± 0.05             0.088
   Platelet (10^9^/L)           281.75 ± 89.1           318 ± 160.74            0.041[\*](#t1f1){ref-type="table-fn"}
   NLR                          2.68 (0.88-34.62)       7.58 (1.36-33.20)       \<0.001[\*](#t1f1){ref-type="table-fn"}
   BLR                          0.03 ± 0.01             0.06 ± 0.06             0.005[\*](#t1f1){ref-type="table-fn"}
   MLR                          0.36 ± 0.18             0.53 ± 0.28             0.001[\*](#t1f1){ref-type="table-fn"}
   PLR                          145.40 (72.10-533.25)   247.89 (97.10-707.11)   0.001[\*](#t1f1){ref-type="table-fn"}

statistically significant (p\<0.05); SD, Standard Deviations; NLR, neutrophil-to-lymphocyte ratio; BLR, basophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

Correlation of hematology markers with FIGO stage of cervical cancer {#sec2-4}
--------------------------------------------------------------------

Partial correlation was used to analyze the correlation between blood parameters (NLR, PLR, BLR, and MLR) against FIGO staging of cervical cancer by controlling age, age at menarche, and parity. There was a statistically significant strong positive correlation between NLR (r = 0.638) and PLR (0.668) with cervical cancer staging (p \< 0.05). These findings illustrate that the increase NLR and PLR will have a tendency to experience higher staging (more advanced disease severity). However, BLR (r=0.362) and MLR (r=0.399) only had a moderate positive correlation to staging from the cervical cancer (lower correlation evidence) (see [Table 2](#T2){ref-type="table"}).

###### 

Correlation between Hematological Markers with FIGO Stage after Adjustment for Age, Age at Menarche, and Parity

  Variable   FIGO Stage           
  ---------- ------------ ------- -----------------------------------------
  NLR        282          0.638   \<0.001[\*](#t2f1){ref-type="table-fn"}
  PLR                     0.668   \<0.001[\*](#t2f1){ref-type="table-fn"}
  MLR                     0.399   \<0.001[\*](#t2f1){ref-type="table-fn"}
  BLR                     0.362   \<0.001[\*](#t2f1){ref-type="table-fn"}

statistically significant (p\<0.05); NLR, neutrophil-to-lymphocyte ratio; BLR, basophil-to-lymphocyte ratio; MLR, monocyte-to- lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

Predictive model of NLR, PLR, BLR, and MLR as hematological markers in the cervical cancer staging {#sec2-5}
--------------------------------------------------------------------------------------------------

Predictive models were performed through ROC curve analysis on NLR, PLR, MLR, and BLR parameters against advance stage of cervical cancer as an outcome in the study ([Figure 1](#F1){ref-type="fig"}). Only NLR and PLR parameters that are feasible to be used as predictive models because they have an area under the curve (AUC\> 0.7) which is higher than other parameters (BLR and MLR). NLR has a sensitivity value of 82% and specificity of 71% with a cut-off value of 3.38. PLR has a sensitivity of 72% and specificity of 70% with a cut off value of 172.05 ([Table 3](#T3){ref-type="table"}).

![ROC Analysis of NLR, PLR, MLR, and BLR as Predictive Values in the Advance Stage of Cervical Cancer](APJCP-20-863-g001){#F1}

###### 

AUC, Cut-off Value, Sensitivity, and Specificity for NLR, PLR, BLR, and MLR in Cervical Cancer Patients

  Parameter   AUC     95% CI      Cut-off value   Sensitivity   Specificity   p
  ----------- ------- ----------- --------------- ------------- ------------- -----------------------------------------
  NLR         0.803   0.70-0.89   3.380           82%           71%           \<0.001[\*](#t3f1){ref-type="table-fn"}
  PLR         0.716   0.60-0.82   172.050         72%           70%           0.001[\*](#t3f1){ref-type="table-fn"}
  BLR         0.679   0.55-0.80   0.034           66%           71%           0.002[\*](#t3f1){ref-type="table-fn"}
  MLR         0.699   0.58-0.81   0.409           69%           63%           0.005[\*](#t3f1){ref-type="table-fn"}

statistically significant (p\<0.05); NLR, neutrophil-to-lymphocyte ratio; BLR, basophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; AUC, area under the curve; CI, confidence interval.

###### 

Risk Analysis Model of NLR, PLR, BLR, and MLR in Advanced Cervical Cancer

  Univariate Model                                                                                             Multivariate Model                
  ------------------ ------------ ------------- ------- ------------ ----------------------------------------- -------------------- ------------ ---------------------------------------
  High               81 (58.7%)   57 (41.3%)    12.22   6.48-23.01   \<0,001[\*](#t4f1){ref-type="table-fn"}   9.02                 2.42-33.64   0.001[\*](#t4f1){ref-type="table-fn"}
  Normal             15 (10.4%)   129 (89.6%)                                                                                                    
  High               69 (48.9%)   72 (51.1%)    4.04    2.37-6.90    \<0.001[\*](#t4f1){ref-type="table-fn"}   2.47                 1.45-4.85    0.032[\*](#t4f1){ref-type="table-fn"}
  Normal             27 (19.1%)   114 (80.9%)                                                                                                    
  High               66 (47.8%)   72 (52.2%)    3.48    2.06-5.87    0.003[\*](#t4f1){ref-type="table-fn"}     1.66                 0.17-7.59    0.56
  Normal             30 (20.8%)   114 (79.2%)                                                                                                    
  High               63 (53.8%)   54 (46.2%)    4.67    2.75-7.91    0,001[\*](#t4f1){ref-type="table-fn"}     2.31                 0.70-7.59    0.165
  Normal             33 (20%)     132 (80%)                                                                                                      

statistically significant (p\<0.05); NLR, Neutrophil-to-lymphocyte Ratio; BLR, Basophil-to-lymphocyte Ratio; MLR, Monocyte-to-lymphocyte Ratio; PLR, Platelet-to-lymphocyte Ratio; CI, Confidence Interval; OR, Odds Ratio.

Risk analysis model of hematological markers as predictive value in the advance stage of cervical cancer {#sec2-6}
--------------------------------------------------------------------------------------------------------

Risk analysis model is based on the cut-off value of the ROC. NLR, PLR, MLR, and BLR values that exceeded the cut-off point will be classified as high level ratio and values below the cut-off point will be classified in the normal level ratio. In a univariate risk analysis model, all high value of blood parameters (NLR, PLR, MLR, and BLR) are significantly associated as a risk factor for invasive cervical cancer (OR\> 1; p\<0.05). In the multivariate model, NLR and PLR have a significant association as a risk factor for invasive cervical cancer.

Discussion {#sec1-4}
==========

The present study include two morphological types of cervical cancer, squamous cell carcinoma and adenocarcinoma, which might affect the laboratory parameters. The difference in the histology of the cancer could affect the prognosis of the patients. However, this study find no significant difference in the distribution of the histological type between the early and advanced stage group. Moreover, the histological type has been found to have no prognostic information (Mabuchi et al., 2011). Furthermore, the inclusion of two histological type of cervical cancer represents the prevalence of the cervical cancer types in the population where squamous cell carcinoma predominates (Spaans et al., 2018). Hence, this inclusion provide useful information for the use of the laboratory parameters in predicting the prognosis of the commonly found cervical cancer in the secondary health services.

The study found a significant decrease in the hemoglobin levels between early and advance stage patients, Moreover, leukocytosis, neutrophilia, thrombocytosis and lymphocytosis were also observed. However, these difference may be caused by the progression of the cervical cancer disease. Furthermore, these parameters are our focus of investigation to predict the progression of the cervical cancer.

It is established that the inflammatory response contributes to the development of the cancer (Yildirim et al., 2014). The systemic inflammatory response was characterized with the infiltration of leukocytes, such as neutrophil and monocytes, which were attracted by the cytokines and chemokines secreted from the tumor cells (Parida and Mandal, 2014). This response is associated with the rearrangement of the circulating white blood cells like the decreased in the lymphocyte count and the increased in the neutrophil count. This was supported by the Tavares-Murta et al., (2010) study findings. They demonstrated that the incidence of leukocytosis, neutrophilia, lymphopenia, and neutrophil to lymphocyte ratio greater than 5 were significantly higher in the advanced stage of cervical cancer (p\<0.001, p\<0.05, p\<0.001, and p\<0.01) (Tavares-Murta BM et al., 2010). A similar finding was found in our study. We observed a higher counts of neutrophil, monocyte and lymphocyte in the invasive than the pre-invasive cancer patients. The Neutrophil Lymphocyte ratio (NLR) found in our study showed a lower cut-off points compare to the previous study. However, the NLR was consistent with the previous finding which is found to be higher in the more severe cancer patients group. Furthermore, the higher Platelet Lymphocyte Ratio (PLR), Basophil Lymphocyte Ratio (BLR) and Monocyte Lymphocyte Ratio (MLR) were found in the invasive cancer patients. Thus, the measurement of the inflammatory response in these hematologic parameters would provide the information of the cervical cancer severity.

The use of hematologic parameter in determining the prognosis and managing the therapy for the cervical cancer have become more common among the clinicians (Nakamura et al., 2018). Lee et al., (2012) have suggested the use of NLR for estimating the mortality and the recurrences of cervical cancer. A high NLR is correlated with the poor prognosis of cervical carcinoma patients (Nakamura et al., 2018; Chun et al., 2017; Nakamura et al., 2015). The pretreatment NLR level is inversely correlated with the survival time in the cervical carcinoma patients (R=-0.538, R2=-0.289, P=0.002). Nakamura et al. found that the progression free and overall survival hazard ratio of 0.317 (95% confidence interval (CI): 0.167 0.602; P\<0.001) and 0.274 (95% CI:0.141-0.530; P\<0.001), respectively (Nakamura et al., 2018). Chun S. et al. found a similar finding with the recurrence free survival hazard ratio of cervical intraepithelial neoplasia for 7.66(95% CI 2.34-25.1, p=0.001) (Chun et al., 2017). Moreover, the NLR can provide a valid prediction on the prognosis of the patient with stage IIB and the metastasis of the lymph nodes. However, the NLR may have an additional value in diagnosing the severity of the cervical cancer. It is proposed that the NLR can be used as a marker for predicting the cancer invasion (Kose et al., 2015). Although the study has demonstrated a higher NLR in the invasive cancer group than the pre-invasive group, there is no significant correlation between the NLR and the cervical lesion invasion (correlation coefficient=0.168, p=0.87). This is contrasted with our finding that show a significant correlation between NLR and the FIGO staging of cervical lesion after adjusted for age, age at menarche and the parity. It is possible that the difference in the patient characteristics and the small sample size may affect the correlation between the NLR and the cervical lesion. Furthermore, the NLR has shown a high sensitivity and specificity of 82% and 71% with the cutoff of 3.38 in predicting the invasiveness of the cervical cancer. Therefore, further research with a bigger sample size is needed to validate the findings.

The PLR depends on the systemic inflammatory response which is highly affected by the cancer response or other inflammatory condition (Sun et al., 2016). These condition would resulted in the misdiagnosis and ineffective or even harmful therapy. However, the research has demonstrated the association between the PLR and the cervical cancer disease based on the thrombocytosis and lymphocytopenia condition as the inflammatory response (Kose et al., 2015; Smith et al., 2008; Zhou et al., 2014; Chen et al., 2016). It is used as a predictor for the lymph node metastasis in the cervical cancer and improve the risk stratification for predicting the survival. The PLR shows significant reduction in recurrence free and overall survival of cervical cancer (p=0.003 and p=0.007, respectively (Chen et al., 2016). In this study, we found a significant correlation with the FIGO stage after adjusted for age, age at menarche and parity (p\<0.001). A similar finding was observed in another study that reported an inverse correlation between the high pretreatment PLR and the survival of the cervical cancer patients following concurrent chemoradiation therapy (R=-0.542, R2=-0.294, P=0.001) (Nakamura et al., 2015).27 Moreover, the sensitivity and specificity of the PLR in differentiating between pre-invasive and invasive lesion is quite high for 72% and 63% (p=0.001). Furthermore, the PLR provides a simple and readily available test for predicting the severity of cervical cancer (Chen et al., 2016).32 Therefore, the PLR can serve as a simple predictor of cervical cancer invasiveness with cautious interpretation.

The MLR and BLR were considered as a novel parameter for the cervical cancer invasiveness. We believed that this study is the first that explore the association between the MLR, BLR and pre-invasive, invasive cancer disease. There is a significant correlation between these parameters with the FIGO classification of the disease after adjusted for age, age at menarche and parity. However, the sensitivity and the specificity of those were below the NLR and PLR. Thus, the independent use of the MLR and BLR would be less reliable.

However, the univariate analysis for the NLR, PLR, MLR, and BLR for risk model showing a significant association between these parameters and the invasiveness of cervical cancer disease. Although the multivariate analysis showed that the BLR and MLR was not significant after adjustment, it would need further research before it can be ruled out as a potential markers for the cervical cancer invasiveness. This may be resulted from the potential bias due to the small sample size and the retrospective design. Hence, a study with bigger sample size and prospective design can provide more insight on these parameters.

In conclusion, the NLR and PLR showed a potential use for predicting the cervical cancer invasiveness. In addition, the MLR and BLR were observed to be independently associated and correlated with the cervical cancer invasiveness. However, the other inflammatory condition and the limitation of this study may affect the result. Therefore, the use of these parameters in predicting the cervical cancer invasiveness warrant for a more comprehensive and prospective research study before further implementation in the clinical settings.
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